- Erratum
- Open access
- Published:
Erratum to: Patient costs of breast cancer endocrine therapy agents under Medicare Part D vs with generic formulations
SpringerPlus volume 4, Article number: 531 (2015)
Erratum to: SpringerPlus (2015) 4:54 DOI 10.1186/s40064-015-0827-8
It has come to our attention that during production of the original article, some of the column headings were missing from Tables 1 and 2. The corrected Tables 1 and 2 can be found below. The publisher apologises for any inconvenience caused.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1186/s40064-015-0827-8.
Rights and permissions
Open access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Nattinger, A.B., Pezzin, L.E., McGinley, E.L. et al. Erratum to: Patient costs of breast cancer endocrine therapy agents under Medicare Part D vs with generic formulations. SpringerPlus 4, 531 (2015). https://doi.org/10.1186/s40064-015-1233-y
Published:
DOI: https://doi.org/10.1186/s40064-015-1233-y